Material and method for treating cancer
Pharmaceutical compositions and methods for sustained release of therapeutic agents for local treatment of cancer diseases involve embedding lyophilized mitomycin C in a slowly releasing biocompatible hydrogel applied to affected tissue. The mitomycin C is lyophilized in a composition using urea as a bulking agent, and the mitomycin C and the bulking agent are present in a ratio of from about 1:7 to about 1:9 in the lyophilized pharmaceutical composition.
1. A method for treating urinary tract cancer, the method comprising:
administering a pharmaceutical composition into an internal body cavity of the urinary tract of a subject in need thereof,
wherein the pharmaceutical composition comprises (b) reconstituted in (a),
wherein (a) is a biocompatible thermoreversible hydrogel comprising
from about 15% to about 35% (w/w) of Poloxamer 407 based on a total weight of the biocompatible thermoreversible hydrogel,
from about 0.01% to about 0.3% (w/w) of hydroxypropylmethylcellulose based on a total weight of the biocompatible thermoreversible hydrogel, and
water,
wherein (b) is a therapeutically effective amount of a lyophilized pharmaceutical composition comprising mitomycin C and a bulking agent,
wherein the bulking agent is urea,
wherein mitomycin C and the bulking agent are present in a ratio of from about 1:7 to about 1:9 in the lyophilized pharmaceutical composition, and
wherein mitomycin C is present in the pharmaceutical composition in a concentration of about 1.33 mg/ml to about 4 mg/ml.
2. The method according to claim 1 , wherein the urinary tract cancer is bladder cancer.
3. The method according to claim 1 , wherein the urinary tract cancer is upper tract urothelial cancer (UTUC).
4. The method according to claim 3 , wherein the biocompatible thermoreversible hydrogel further comprises PEG-400 in an amount of from about 0.1% to about 1.8% (w/w) based on a total weight of the biocompatible thermoreversible hydrogel.
5. The method according to claim 2 , wherein mitomycin C and the bulking agent are present in a ratio of about 1:8 in the lyophilized pharmaceutical composition.
6. The method of claim 2 , wherein the pharmaceutical composition is administered via a catheter.
7. The method according to claim 3 , wherein the biocompatible thermoreversible hydrogel further comprises PEG-400 in an amount of from about 0.1% to about 1.8% (w/w) based on a total weight of the biocompatible thermoreversible hydrogel.
8. The method according to claim 3 , wherein mitomycin C and the bulking agent are present in a ratio of about 1:8 in the lyophilized pharmaceutical composition.
9. The method of claim 3 , wherein the pharmaceutical composition is administered via a catheter.